104 related articles for article (PubMed ID: 31306192)
21. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Schmidt-Hegemann NS; Fendler WP; Buchner A; Stief C; Rogowski P; Niyazi M; Eze C; Li M; Bartenstein P; Belka C; Ganswindt U
Radiat Oncol; 2017 Nov; 12(1):176. PubMed ID: 29126446
[TBL] [Abstract][Full Text] [Related]
22. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
23. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
24. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis.
Pereira Mestre R; Treglia G; Ferrari M; Pascale M; Mazzara C; Azinwi NC; Llado' A; Stathis A; Giovanella L; Roggero E
Eur J Clin Invest; 2019 Mar; 49(3):e13063. PubMed ID: 30580449
[TBL] [Abstract][Full Text] [Related]
25. Schmorl's Node: Confusion Still Persists in 68Ga-Prostate-Specific Membrane Antigen Ligand PET/CT.
Sahoo MK; Ahlawat K; Yadav R; Gajendra S
Clin Nucl Med; 2018 Sep; 43(9):679-681. PubMed ID: 30036258
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous whole-body
Freitag MT; Kesch C; Cardinale J; Flechsig P; Floca R; Eiber M; Bonekamp D; Radtke JP; Kratochwil C; Kopka K; Hohenfellner M; Stenzinger A; Schlemmer HP; Haberkorn U; Giesel F
Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):340-347. PubMed ID: 29038888
[TBL] [Abstract][Full Text] [Related]
27. The phytological future of prostate cancer staging: PSMA-PET and the dandelion theory.
Sathianathen NJ; Geurts N; Nair R; Lawrentschuk N; Murphy DG; Lamb AD
Future Oncol; 2017 Aug; 13(20):1801-1807. PubMed ID: 28762288
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-Prostate-Specific Membrane Antigen PET/CT: Incidental Finding of a Liposarcoma.
Militano V; Afaq A; Bomanji J
Clin Nucl Med; 2019 Feb; 44(2):e90-e92. PubMed ID: 30608915
[TBL] [Abstract][Full Text] [Related]
29. Physiologic distribution of PSMA-ligand in salivary glands and seromucous glands of the head and neck on PET/CT.
Klein Nulent TJW; Valstar MH; de Keizer B; Willems SM; Smit LA; Al-Mamgani A; Smeele LE; van Es RJJ; de Bree R; Vogel WV
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):478-486. PubMed ID: 29523427
[TBL] [Abstract][Full Text] [Related]
30. EBONI: A Tool for Automated Quantification of Bone Metastasis Load in PSMA PET/CT.
Hammes J; Täger P; Drzezga A
J Nucl Med; 2018 Jul; 59(7):1070-1075. PubMed ID: 29242401
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
32. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
33. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
Turkbey B; Mena E; Lindenberg L; Adler S; Bednarova S; Berman R; Ton AT; McKinney Y; Eclarinal P; Hill C; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Jacobs PM; Wood BJ; Pinto PA; Pomper MG; Choyke PL
Clin Nucl Med; 2017 Oct; 42(10):735-740. PubMed ID: 28806263
[TBL] [Abstract][Full Text] [Related]
34. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
35. Incidental abnormal FDG uptake in the prostate on 18-fluoro-2-deoxyglucose positron emission tomography-computed tomography scans.
Kang PM; Seo WI; Lee SS; Bae SK; Kwak HS; Min K; Kim W; Kang DI
Asian Pac J Cancer Prev; 2014; 15(20):8699-703. PubMed ID: 25374193
[TBL] [Abstract][Full Text] [Related]
36.
Herlemann A; Wenter V; Kretschmer A; Thierfelder KM; Bartenstein P; Faber C; Gildehaus FJ; Stief CG; Gratzke C; Fendler WP
Eur Urol; 2016 Oct; 70(4):553-557. PubMed ID: 26810345
[TBL] [Abstract][Full Text] [Related]
37. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT.
Eiber M; Herrmann K; Calais J; Hadaschik B; Giesel FL; Hartenbach M; Hope T; Reiter R; Maurer T; Weber WA; Fendler WP
J Nucl Med; 2018 Mar; 59(3):469-478. PubMed ID: 29123012
[TBL] [Abstract][Full Text] [Related]
38. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
39. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
40. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer.
Schmidkonz C; Cordes M; Beck M; Goetz TI; Schmidt D; Prante O; Bäuerle T; Uder M; Wullich B; Goebell P; Kuwert T; Ritt P
Clin Nucl Med; 2018 Apr; 43(4):225-231. PubMed ID: 29401151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
